2,095
Views
1
CrossRef citations to date
0
Altmetric
Case Report

De novo lymphoid blastic phase chronic myeloid leukemia: report and contemporary discussion

, , , , , , , , , , & show all
Pages 1259-1262 | Received 22 Apr 2022, Accepted 14 Nov 2022, Published online: 30 Nov 2022

References

  • Jabbour E, Kantarjian H, O'Brien S, et al. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood. Jan 2006;107(2):480–482. doi:10.1182/blood-2005-05-1816.
  • Alfayez M, Richard-Carpentier G, Jabbour E, et al. Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia. Br J Haematol. 2019;187(4):543–545.
  • Ohanian M, Kantarjian HM, Quintas-Cardama A, et al. The clinical impact of time to response in De Novo accelerated phase chronic myeloid leukemia (CML-AP). Blood. 2012;120(21):72–72. doi:10.1182/blood.V120.21.72.72.
  • Hovorkova L, Zaliova M, Venn NC, et al. Monitoring of childhood ALL using. Blood. 2017;129(20):2771–2781. doi:10.1182/blood-2016-11-749978.
  • Sloma I, Jiang X, Eaves AC, et al. Insights into the stem cells of chronic myeloid leukemia. Leukemia. Nov 2010;24(11):1823–1833. doi:10.1038/leu.2010.159.
  • Sasaki K, Jabbour EJ, Ravandi F, et al. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2016;122(23):3650–3656. doi:10.1002/cncr.30231.
  • Jabbour E, Sasaki K, Short NJ, et al. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2021;127(12):2025–2038. doi:10.1002/cncr.33469.
  • Short NJ, Jabbour E, Sasaki K, et al. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016;128(4):504–507. doi:10.1182/blood-2016-03-707562.
  • Short NJ, Kantarjian H, Jabbour E. Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms. Leukemia. 11 2021;35(11):3044–3058. doi:10.1038/s41375-021-01277-3.
  • Sasaki K, Kantarjian HM, Short NJ, et al. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer. 2021;127(15):2648–2656. doi:10.1002/cncr.33529.
  • Short NJ, Kantarjian H, Konopleva M, et al. Updated results of a phase II study of ponatinib and blinatumomab for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2021;138(Supplement 1):2298–2298. doi:10.1182/blood-2021-153795.
  • Foà R, Bassan R, Vitale A, et al. Dasatinib-Blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020;383(17):1613–1623. doi:10.1056/NEJMoa2016272.